Ocular Therapeutix Shares Rise 15% After Dextenza Trial In China

By Ben Glickman Shares of Ocular Therapeutix rose Tuesday after a trial of its drug Dextenza met its primary endpoint. The stock was up 15% to $2.85 in...

Related Keywords

China ,Ben Glickman ,Dayao Zhao , ,Ocular Therapeutix ,Amed Therapeutics ,Med Chief Executive Dayao Zhao ,Article Normal ,Pharmaceuticals ,Healthcare Life Sciences ,Specialized Drugs Medications ,Financial Performance ,Share Price Movement Disruptions ,New Products Services ,Research Development ,Corporate Industrial News ,Products Services ,New Product Service Testing ,Equity Markets ,Commodity Financial Market News ,Content Types ,Factiva Filters ,C Amp Ampe Exclusion Filter ,C Amp Ampe Industry News Filter ,Synd ,Hocul ,Us67576a1007 ,Share Price Movement ,Disruptions ,New Products ,Services ,Research ,Development ,Corporate ,Industrial News ,Products ,New Product ,Service Testing ,Commodity ,Financial Market News ,Healthcare ,Life Sciences ,Specialized Drugs ,Medications ,